To Evaluate the Safety, Tolerability and PK of GT20029 Gel and Solution in Healthy Subjects
A Randomized, Double-blind, Placebo-controlled Phase Ⅰ Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of GT20029 Gel and Solution for Single and Multi Dose External Administration in Healthy Subjects
In the register
The register attaches this trial to GT20029 (Kintor Pharmaceutical), currently at “Phase 2” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 1
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
- Participants (registry)
- 92
- Start
- July 2021
- Primary completion
- August 2022
- Study completion
- April 2023
- Last registry update
- October 2024
- Countries
- China
Conditions studied: Acne, Alopecia
Interventions: GT20029, GT20029 matching placebo
Other trials of GT20029
To Evaluate the Efficacy and Safety of GT20029 Solution in the Treatment of Androgenetic Alopecia (AGA) in Chinese Adult Males
Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.